The American Urological Association Annual Meeting took place May 3-6, 2024, in San Antonio, Texas, where data across the field of urologic oncology were presented.
The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 ...
Medical experts discuss a patient case highlighting a 68-year old woman who is uninterested in transplantation and treatment ...
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second ...
Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder ...
In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction ...
A clinical trial to evaluate EIS-12656 in patients with specific types of advanced solid tumors will begin following the ...
Tina Cascone, MD, PhD, discusses who was included in the phase 3 CheckMate-77T trial and the key end points of the study.
Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder ...
Apalutamide with androgen deprivation therapy following radical prostatectomy led to a biochemical recurrence-free survival rate of 100% after 2 years among patients with high-risk prostate cancer.
Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 ...
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results